As the CEO of Adaptive Biotechnologies, Chad Robins has shown a knack for turning really good ideas into a viable business. But even Robins admits that he makes for an… Read More
Good Therapeutics, a new Seattle biotech startup that aims to develop protein drugs that act only when needed, raised $11 million in an equity round, according to a new SEC… Read More
Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading. Quarterly revenues came in at $175 million, above Wall Street expectations… Read More
Researchers at the Fred Hutchinson Cancer Research Center led by Dr. Cyrus Ghajar recently uncovered promising new science in the battle against metastatic breast cancer. Their findings, published today in… Read More
Although Steve Pergam grew up with parents who were both physicians, he was never pushed to be a doctor as a kid growing up in Omaha, Neb. He credits a… Read More
Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb (BMS) intends to buy Celgene, the parent company of Juno… Read More
For 30 years, scientists have been trying to unleash the promise of Interleukin-2 (IL-2), a powerful protein that fights cancer but is highly toxic. Researchers at the University of Washington… Read More
Adaptive Biotechnologies has signed a $300 million collaborative licensing agreement with Genentech to develop highly personalized cancer therapies. In addition to the up-front payment, Adaptive could receive up to $2… Read More
Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an agreement with drug giant Pfizer that includes $15 million in… Read More
CTI BioPharma announced Thursday that it will let go of half its employees in order to create more runway to develop its experimental drug Pacritinib, which treats the blood cancer… Read More
Billionaire philanthropist Paul Allen died two months ago, but before he passed away, he passed along a $125 million commitment to a new research frontier: the Allen Institute for Immunology.… Read More
As a journalist, Luke Timmerman has covered biotech for more than 17 years. Now, the Timmerman Report founder is making headlines for his efforts to raise money for cancer research.… Read More
It’s notable that the newest class of Allen Distinguished Investigators, announced today by the Paul G. Allen Frontiers Group, includes researchers who are developing new treatments for lymphoma. Lymphoma is… Read More
For the fifth year in a row, Boeing and the International Space Station’s U.S. national laboratory are partnering to pay out up to $500,000 in grants for startup research in… Read More
“I felt as bulletproof as most people under thirty. I took my health for granted.” That’s how Paul Allen, the co-founder of Microsoft and a leader in science, technology and… Read More
Nine years after he underwent treatment for non-Hodgkin’s lymphoma, a potentially fatal but treatable form of cancer, Microsoft co-founder Paul Allen says the disease has returned. On Twitter and in… Read More
Scientists have developed a technique that can analyze fluid from a single human cell to identify its proteins — which could open the way for tracking the progression of cancer one… Read More
News Brief: Grail, a biotech company with early backing from Microsoft co-founder Bill Gates and Amazon founder Jeff Bezos, says it’s raised $300 million in an oversubscribed Series C financing… Read More
Seattle biotech journalist Luke Timmerman reached new heights Tuesday in his efforts to raise awareness for cancer research by successfully summiting Mount Everest. A series of tweets and photographs showed… Read More
In December of 2012, Su-In Lee was working at the University of Washington in Seattle. One day, she got the kind of call everyone fears: Her father, Cheol Lee, was… Read More
Two clinical studies have provided evidence suggesting that an experimental precision-medicine drug called larotrectinib can fight soft-tissue tumors regardless of the patient’s age or the type of tumor. Seattle Children’s… Read More
TAE Technologies, the California-based fusion energy company backed by Microsoft co-founder Paul Allen, has spawned a spinoff focusing on a novel type of cancer therapy. The spinoff, TAE Life Sciences,… Read More
AUSTIN, Texas — Joe Biden may no longer be vice president, but he’s still leading the charge for his cancer moonshot, and for science funding as well. “The United States government,… Read More
Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the company’s small-molecule breast cancer treatment for about $614 million, or… Read More
A study conducted by Fred Hutchinson Cancer Research Center, with contributions from researchers across North America, has found stark differences between children and adults with acute myeloid leukemia (AML), a… Read More
Anand Prakash is taking an unexpected path toward building GrailAI, a startup that he recently launched to fight cancer. He’s setting up shop in Bellevue, Wash. instead of his hometown… Read More
The fight against cancer isn’t just about drugs and genetics. It’s also about wearable devices, health-savvy chatbots, machine learning and one of the biggest challenges that cloud computing will ever… Read More
The president and director of Seattle’s Fred Hutchinson Cancer Research Center, Gary Gilliland, is bringing big-data experts on board to make good on his controversial prediction that there could be cures and… Read More
It was an unusually busy week for news in the world of business, technology and science. Join us on this episode of GeekWire’s Week in Geek podcast to catch up… Read More
University of Washington researchers have created a smartphone app that can let users screen themselves for pancreatic cancer and other diseases by taking a selfie. But not just any selfie.… Read More